We are live on !
Find out more
Jim Simons Renaissance Technologies
AUM
$72.6B
Turnover
31.08%
1-Year Est. Return
54.88%
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
This Fund
S&P 500
This Quarter Est. Return
+4.89%
1 Year Est. Return
+54.88%
3 Year Est. Return
+169.34%
5 Year Est. Return
+186.18%
10 Year Est. Return
+887.93%
AUM
$63.2B
AUM Growth
+$6.63B
(+12%)
Cap. Flow
+$5.07B
Cap. Flow % of AUM
Cap. Flow %
8.02%
Top 10 Holdings %
Top 10 Hldgs %
7.17%
Holding
3,715
New
418
Increased
1,791
Reduced
991
Closed
493
Avg Time Held
1.8
years
Top 10 Avg Time Held
1.3
years
Top 20 Avg Time Held
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.75% |
| 2 | Technology | 13.74% |
| 3 | Healthcare | 12.69% |
| 4 | Industrials | 11.52% |
| 5 | Consumer Discretionary | 8.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Mastercard
MA
$546B
| $582M | 0.92% |
5,641,400
-2,700
| -0% | -$280K |
2013 Q2
14 quarters
|
|
2
Colgate-Palmolive
CL
$74.7B
| $553M | 0.88% |
8,453,600
+1,605,600
| +23% | +$110M |
2013 Q2
14 quarters
|
|
3
Novo Nordisk
NVO
$173B
| $500M | 0.79% |
27,891,800
-1,415,200
| -5% | -$25.7M |
2013 Q2
14 quarters
|
|
|
LLTC
4
DELISTED
Linear Technology Corp
LLTC
| $482M | 0.76% |
7,733,600
-981,300
| -11% | -$59.8M |
2013 Q2
14 quarters
|
|
5
Costco
COST
$441B
| $451M | 0.71% |
2,819,713
+733,500
| +35% | +$112M |
2013 Q2
14 quarters
|
|
6
NetEase
NTES
$78.7B
| $434M | 0.69% |
10,069,500
+104,000
| +1% | +$4.96M |
2013 Q2
14 quarters
|
|
|
7
Johnson & Johnson
JNJ
$616B
| $394M | 0.62% |
3,423,100
+1,948,000
| +132% | +$225M |
2015 Q3
5 quarters
|
|
|
8
Gilead Sciences
GILD
$190B
| $378M | 0.6% |
5,274,948
+3,327,900
| +171% | +$247M |
2014 Q4
8 quarters
|
|
9
Walt Disney
DIS
$191B
| $378M | 0.6% |
3,623,907
+970,700
| +37% | +$94.6M |
2016 Q2
2 quarters
|
|
10
Chubb
CB
$138B
| $378M | 0.6% |
2,857,461
+1,147,400
| +67% | +$146M |
2015 Q1
7 quarters
|
|
|
AET
11
DELISTED
Aetna Inc
AET
| $353M | 0.56% |
2,842,782
+1,737,100
| +157% | +$208M |
2015 Q3
5 quarters
|
|
12
NVIDIA
NVDA
$5.32T
| $330M | 0.52% |
123,788,000
-4,196,000
| -3% | -$8.77M |
2013 Q4
12 quarters
|
|
13
VeriSign
VRSN
$27.8B
| $324M | 0.51% |
4,263,376
-450,000
| -10% | -$35.6M |
2013 Q2
14 quarters
|
|
14
Cboe Global Markets
CBOE
$33.2B
| $324M | 0.51% |
4,386,100
-79,900
| -2% | -$5.5M |
2013 Q2
14 quarters
|
|
|
MON
15
DELISTED
Monsanto Co
MON
| $302M | 0.48% |
2,865,800
+2,080,400
| +265% | +$213M |
2016 Q2
2 quarters
|
|
16
Humana
HUM
$51.2B
| $298M | 0.47% |
1,460,300
+546,596
| +60% | +$104M |
2015 Q2
6 quarters
|
|
17
Alphabet (Google) Class A
GOOGL
$4.07T
| $281M | 0.44% |
7,084,000
-3,396,960
| -32% | -$136M |
2016 Q1
3 quarters
|
|
18
Walmart Inc
WMT
$936B
| $274M | 0.43% |
11,877,300
+3,493,800
| +42% | +$81.5M |
2016 Q1
3 quarters
|
|
19
Duke Energy
DUK
$94.6B
| $264M | 0.42% |
3,396,267
+113,300
| +3% | +$8.68M |
2014 Q1
11 quarters
|
|
20
F5
FFIV
$26B
| $261M | 0.41% |
1,804,874
+286,800
| +19% | +$38.9M |
2014 Q3
9 quarters
|
|
21
Amgen
AMGN
$235B
| $260M | 0.41% |
1,778,645
-117,696
| -6% | -$17.7M |
2013 Q2
14 quarters
|
|
22
Domino's
DPZ
$10.2B
| $257M | 0.41% |
1,613,500
+188,900
| +13% | +$30.7M |
2013 Q2
14 quarters
|
|
23
Crown Castle
CCI
$33.8B
| $256M | 0.41% |
2,954,903
+1,128,703
| +62% | +$98.9M |
2015 Q1
7 quarters
|
|
24
Entergy
ETR
$50.8B
| $256M | 0.4% |
6,964,600
+517,000
| +8% | +$18.5M |
2014 Q3
9 quarters
|
|
25
American Electric Power
AEP
$69.6B
| $245M | 0.39% |
3,887,600
+558,392
| +17% | +$34.4M |
2014 Q3
9 quarters
|
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,791 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 15% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 493 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.